October      

• Invited to exhibit in "Taiwan Innotech Expo"

• Invited to participate in 2022 TREE matchmaking, DOIT, MOEA

September

• Invited to participate in the business activity of Lithuanian Ministry of Economy and Innovation delegation

June

• Selected as Taiwan startups to participate in 2022 SelectUSA Investment Summit

February    

• MOEA agreed to exclusive authorization of 45 patents for 7 families and for 28 countries to BELX

January

• Listed in Taiwan Tech Arena Best 100 and participated in CES 2022 with TTA

November  

• Initiated long-term toxicology testing Obtained the trademark registration right of "BELX^®" in China

October

• Awarded the 3^rd Place of Taiwan Research-Institute Entrepreneur, DOIT, MOEA

August       

• Selected to participate in 2021 SelectUSA Investment Summit
• Selected to participate in 2021 FINDIT speed dating matchmaking
• Awarded Judges’ Choice from Taiwan Research-Institute Entrepreneur Ecosystem Program, DOIT, MOEA

May     

• Obtained the trademark registration right of "BELX^®" in Taiwan

• Successfully technology transferred the GACP plantation from Council of Agriculture, Executive Yuan

March    

• Patent application for structures of major active ingredients

February

• Obtained the trademark registration right of "BELX^®" in HongKong

December   

• Awarded Best Startup from ITIC, ITRI

September  

• Completed A⁺ Industrial Innovative R&D Program - Fast Track Clinical Trial Project of the Department of Industrial Technology (DOIT) approved by MOEA

July

• Awarded for the 4th G Camp Growing Global Go, Small and Medium Enterprise Administration, MOEA

June

• TAF testing laboratory (3607) passed the ISO 17025 annual supervision and evaluation

• Selected to participate in the 2020 BIO DIGITAL (North America)

April         

• Cooperated with Council of Agriculture, Executive Yuan to carry out the medicinal material GACP plantation

• Completed phase I clinical trial of botanical new drug BEL-X

December 

• Global Top 100 Science and Technology Innovation Competition - Taiwan Session, 3^rd place awarded.

• TAF testing laboratory (3607) ISO17025 accredited.

October

• Completed Project of Subsidies & Incentives for Taipei, Industry Department of Economic Development, Taipei City Government

November

• Redefining Early-Stage Investment (RESI) Innovation Challenge - Taipei Session, selected for pitch.

• Funding support for Small Business Innovation R & D Program (SBIR) by Small and Medium Enterprise Administration, MOEA

September

• China BioMed Innovation and Investment Conference (CBIIC), selected for roadshow.

November

• Approved as a biotech new drug development company by MOEA

• Dr. Shau-feng Chang, CEO, wins MOEA’s Seventh Female Entrepreneurship Elite Competition - New Venture Group - Science and Technology Innovation award.

October

• Small Business Innovation R & D Program (SBIR) approved by the Small Business Division of MOEA with funding support

September

• Funding support by Taipei Industrial Development R & D Subsidy Program of the Bureau of Economy of Taipei City Government

January

• A⁺ Industrial Innovative R&D Program - Fast Track Clinical Trial Project of the Department of Industrial Technology (DOIT) approved by MOEA with funding support

November

• Approval for establishment of park branch company by the Hsinchu Science and Technology Industrial Park of the Ministry of Science and Technology.

July

• Recruitment of phase I clinical trial for botanical new drug BEL-X started.

May

• Phase I clinical trial application (IND) of botanical new drug BEL-X approved by TFDA

February

• Phase I clinical trial application of botanical new drug BEL-X approved by the NTUH IRB

January

• Phase I clinical trial application of botanical new drug BEL-X approved by the NCKUH IRB

September

• Signed exclusive technology transfer agreement with ITRI

May

• Stationed in the Incubation Center on ITRI Chung-Hsing Campus.

March

• BELX Bio-pharmaceutical (Taiwan) Corporation established

December

• Phase I clinical trial application (IND) of botanical new drug BEL-X approved by the US FDA

2014-2015

• Preparation for Clinical Trials of Botanical New Drug BEL-X initiated by ITRI

2001-2013

• Collaboration with National Taiwan University Hospital in Hepatitis B and liver cancer efficacy studies

2009-2012

• Liver Cancer and Anti-Inflammatory Chinese Herbal Medicine Program funded by MOEA

2005-2008

• Development of new anti-viral and anti-inflammatory Chinese herbal medicines and establishment of modern technology platform funded by MOEA

2000-2004

• Development of New Chinese Medicine for Liver Diseases and Asthma funded by the Ministry of Economic Affairs (MOEA)